Cultivating the Best Science is Our Best Hope
“UMDF is the largest funder of mitochondrial research outside of the federal government. In the last few years, discovery has streamlined the diagnosis for many and allowed designer therapies to be developed for several rare diseases that may be translatable to mitochondrial diseases. The Roadmap to a Cure provides direction for obtaining a diagnosis, developing care pathways for patients and finding therapies to alleviate symptoms.”
Dr. Bruce H. Cohen
Chair, UMDF Scientific & Medical Advisory Board
The pathway to a mitochondrial disease diagnosis is not standardized.
Create a better diagnostic scenario to identify and characterize mitochondrial disease patients based on health information, genetic testing and bio samples.
There is an absence of well-controlled studies within the field and no licensed therapies for mitochondrial disease in the United States.
Coordinate stakeholders in academia, government and the drug development industry to address validated outcome measures, patient-report outcomes and regulatory guidance to gain treatments more efficiently and quickly.
Clinical care for mitochondrial disease patients is often inconsistent, and insurance reimbursement for rare disease care is challenging.
Leverage the national focus on personalized medicine to develop programs and tools that will advance, optimize and lead to standards of patient care for the mitochondrial disease community.
Clinical Trial Opportunities for Patients
Our best hope for finding treatments and cures is clinical trials. For research studies to be effective, a large amount of data from a large pool of participants is essential. We urge patients to join the fight and engage in clinical trials to help make a difference for future generations.
Stay up-to-date on the latest news and updates on clinical trials. Visit the UMDF Clinical Trials page.
Annual UMDF Grant Prize Winners
2023 Prize Winner
Conor Ronayne, PhD
Dana-Farber Cancer Institute,
Harvard Medical School
2022 Prize Winner
Sara Carli, PhD
Mitochondria have their own genetic material, the mitochondrial DNA (mtDNA). Having too little mtDNA is one of the causes that drives the onset of Mitochondrial Depletion Syndromes (MDSs). Patients with MDS experience a spectrum of symptoms which generally lead to death in a few months. mtDNA depletion could be due to a defect in the production of a primary building block or gene of the mitochondrial DNA. Currently, there are no animal models present to better understand MDS or to test the effectiveness of therapeutic treatments. This project proposes to create a mouse model that will be used to better understand the progression of MDS. With a mouse model available I will then test the effectiveness of gene therapy, an innovative therapeutic approach to restoring the defective gene that causes MDS.
2021 Prize Winner
Lia Mayorga, MD, PhD
2020 Prize Winner
Kinsley Christopher Belle
Our objective is to determine how internal factors, such as development and cell specification cues, as well as external stimulus, oxygen levels, energy substrates, and drug compounds influence mitochondria heteroplasmy. Our preliminary assessments suggest that cell-type development and cell division influence heteroplasmy in developing tissues, additionally our work on cell conditions, and small molecules has yielded promising preliminary results for possible therapeutics. This body of work serves as a template for discovering compounds that reduce mitochondrial heteroplasmy and thus disease burden in patients.
2019 Prize Winner
Ecole Polytechnique Federale de Lausanne
Award Winners at MitoMed 2023
Beyond accelerators, UMDF also announced seven other award winners at MitoMed 2023, including:
- Vanguard Award – Robert K. Naviaux, MD, PhD
- Principal Investigator Grant Award ($100,000) – Anthony Grillo, PhD
- Clinical Trial Readiness Grant Award Winner ($100,000) – Anthony Ford-Hutchinson, PhD
Interested in applying for a UMDF Research Grant?
Your Dollars at Work
Your donations power our ability to support science dedicated to mitochondrial disease research.
million in grants awarded
million stimulated in government grant follow on funding
labs funded and launched
million dedicated to Leigh Syndrome Roadmap Initiative
Making an Impact in Drug Development
UMDF recognizes industry as an essential partner in developing treatments and cures for mitochondrial disease.
Industry Advisory Council
Facilitating Drug Development
There is a need to generate more urgency within the drug industry to invest and develop therapeutic treatments focused on mitochondrial disease.
No single organization can take on mitochondrial disease alone. UMDF has gathered the leading mitochondrial disease patient advocacy groups from around the globe to form and fund The Leigh Syndrome International Consortium. This Roadmap to a Cure project showcases our active dedication to find the best science wherever it is located in the world.
UMDF interacts with multiple organizations and is the nucleus of many infrastructure projects dedicated to mitochondrial disease clinical research and patient care. UMDF is collaborating with key stakeholders to create a single hub essential for sharing and dispersing critical information to benefit the entire mitochondrial disease community.